BeOne Medicines (ONC) director sells 212 ADS to cover tax withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BeOne Medicines Ltd. director Sanders Corazon (Corsee) D. reported a small tax-related share sale. On May 22, 2026, the director sold 212 American Depositary Shares at $309.5896 per ADS, with each ADS representing 13 Ordinary Shares. The sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, rather than a discretionary market trade.
Following this transaction, the director holds 54,470 Ordinary Shares directly and no American Depositary Shares. The footnotes state that the restricted share units vest based on service on the board, with potential accelerated vesting upon a change in control or certain termination events.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 212 shares ($65,633)
Net Sell
2 txns
Insider
Sanders Corazon (Corsee) D.
Role
null
Sold
212 shs ($66K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | American Depositary Shares | 212 | $309.5896 | $66K |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 0 shares (Direct, null);
Ordinary Shares — 54,470 shares (Direct, null)
Footnotes (1)
- Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.
Key Figures
ADS sold: 212 American Depositary Shares
Sale price per ADS: $309.5896 per ADS
Post-transaction Ordinary Shares: 54,470 Ordinary Shares
+1 more
4 metrics
ADS sold
212 American Depositary Shares
Open-market sale on May 22, 2026
Sale price per ADS
$309.5896 per ADS
Price reported for the 212 ADS sale
Post-transaction Ordinary Shares
54,470 Ordinary Shares
Shares held directly after the transaction
ADS-to-Ordinary ratio
1 ADS = 13 Ordinary Shares
Equivalence disclosed in footnote
Key Terms
American Depositary Shares, restricted share unit, mandatory tax withholding provision, change in control
4 terms
mandatory tax withholding provision financial
"The sale was effected pursuant to a mandatory tax withholding provision"
change in control financial
"Unvested securities are subject to accelerated vesting upon a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
FAQ
What insider transaction did BeOne Medicines (ONC) disclose for director Sanders Corazon?
BeOne Medicines director Sanders Corazon reported selling 212 American Depositary Shares. The transaction occurred on May 22, 2026, and was executed to satisfy mandatory tax withholding obligations tied to the vesting of a restricted share unit award rather than a discretionary open-market sale.
At what price were the BeOne Medicines (ONC) ADS sold in this insider transaction?
The 212 American Depositary Shares were sold at $309.5896 per ADS. Each ADS represents 13 Ordinary Shares of BeOne Medicines, so the reported price reflects the value of the underlying Ordinary Shares bundled into each ADS unit.